shares erased a decline as a strong quarterly performance more than offset a lower profit outlook amid litigation costs. The stock rose as much as 1.2%.didn’t engage in an anticompetitive conspiracy
to delay generic versions of the HIV drugs. However, before the case went to trial, the companies reached a last-minute deal with major pharmacy chains and direct purchases. Gilead paid $525 million in settlements, according to a second-quarter earnings release, which shaved 32 cents off of per-share earnings.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Europe markets expected to open lower as investors digest earnings and U.S. rating downgradeEuropean markets are expected to open lower Wednesday as investors continue to digest earnings and the U.S. rating downgrade.
Consulte Mais informação »